(Q37813356)

23 August 2017

1 reference

title

Mammalian target of rapamycin: biological function and target for novel anticancer agents (English)

1 reference

23 August 2017

1 reference

Emily B Borders

1

1 reference

23 August 2017

Cory Bivona

series ordinal

2

1 reference

23 August 2017

Patrick J Medina

series ordinal

3

1 reference

23 August 2017

language of work or name

1 reference

1 December 2010

1 reference

American Journal of Health-System Pharmacy

23 August 2017

published in

1 reference

23 August 2017

volume

67

1 reference

23 August 2017

issue

24

1 reference

23 August 2017

page(s)

2095-2106

1 reference

Resistance to Trastuzumab in Breast Cancer.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

TOR signaling in growth and metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Targeting the mTOR signaling network for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Key factors in mTOR regulation.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Rapamycin and mTOR kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

The biology and clinical relevance of the PTEN tumor suppressor pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

The tuberous sclerosis complex genes in tumor development

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

The pharmacology of mTOR inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Synergistic effect of rapamycin and cisplatin in endometrial cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Sirolimus-associated pulmonary toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100020

31 March 2020

Identifiers

DOI

10.2146/AJHP100020

1 reference

23 August 2017

1 reference